AlphAIalphai — Financial news for AI agents
SEC EDGAR 8-KJUN 302 min read$RCKT

ROCKET PHARMACEUTICALS, INC. (RCKT): Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

ROCKET PHARMACEUTICALS, INC. (RCKT) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. false 0001281895 0001281895 2026-06-24 2026-06-24 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 24, 2026 R

Original reporting
SEC EDGAR 8-K
Published Jun 30, 2026, 9:16 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 30, 2026, 9:21 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefCorporate actions
Primary signal
$RCKT
Neutral
medium confidence
Mentioned
$RCKT
Relevance
6/10
alphai data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$RCKTNeutralLow
01

Why it matters

The change affects the Principal Accounting Officer role and could influence investor perception of financial reporting continuity, but it does not include any new earnings, guidance, or operational metrics.

02

Market read

This is a governance/finance leadership transition disclosure with no stated financial impact, so it is unlikely to drive a major repricing by itself.

03

What to watch

The filing notes no new compensatory arrangements and no disclosed related-party transactions, which reduces the likelihood of immediate negative surprises.

Relevance 6/10Novelty 4/10Timing: effective dates in early/mid-July 2026

Background

Rocket filed an SEC Form 8-K (Item 5.02) covering officer departure and appointment tied to finance/accounting leadership.

Company-level read

Ticker impact

$RCKTNeutralMedium confidence
Context

Rocket Pharmaceuticals disclosed VP of Finance resignation effective July 7, 2026 and appointed Joseph Manhede as Principal Accounting Officer effective July 8, 2026.

Expected impact

Likely limited near-term impact; any reaction should be small unless investors view the change as a control-risk or succession issue.

Evidence & confidence

The 8-K is a routine officer appointment/departure disclosure with no compensatory changes and no stated accounting-policy or restatement risk.

Market effects

Sector

Minimal; this is company-specific governance/finance staffing rather than a sector regulatory or clinical catalyst.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

Even without stated issues, a sudden VP of Finance resignation could reflect internal friction; traders may watch for follow-on filings (e.g., control weaknesses, restatements).

Key entities

  • company
    Rocket Pharmaceuticals, Inc.

    Nasdaq-listed biopharmaceutical company filing the 8-K for officer departure/appointment.

  • executive
    John Militello

    Resigned as VP of Finance, Senior Controller, Treasurer, and Principal Accounting Officer effective July 7, 2026.

  • executive
    Joseph Manhede

    Appointed Principal Accounting Officer effective July 8, 2026; previously Associate Vice President, Corporate Controller.

Read at source← All news

Related articles

SEP 4
$RCKTHighAI 9/10

RCKT Stock Dives Despite Gene Therapy Approval — Wall Street Dismisses Sell-Off

Rocket Pharmaceuticals (RCKT) shares fell 22% despite FDA approval of its gene therapy Kresladi for a rare pediatric disorder. The company received a Rare Pediatric Disease Priority Review Voucher. Analysts from Wedbush and LifeSci Capital maintained 'Outperform' ratings, citing the milestone and potential financial benefits. RCKT stock has dropped 53% in the past year.

stocktwits.com2 min
SEP 2
$RCKTMedAI 8/10

Rocket amended complaint alleges UWM targeted Mr. Cooper borrowers

Rocket amended its complaint against UWM, alleging UWM breached agreements by targeting Mr. Cooper borrowers for refinancing, causing prepayment rates 2.5x higher. Rocket claims $100M in damages, citing UWM's initiatives like Refi75 and KEEP. UWM denies allegations, calling them baseless. Rocket acquired Mr. Cooper for $14.2B in 2025.

housingwire.com3 min
AUG 10
$RCKTMed

ROCKET PHARMACEUTICALS, INC. (RCKT): Results of Operations and Financial Condition

ROCKET PHARMACEUTICALS, INC. (RCKT) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Rocket Pharmaceuticals Reports Second Quarter 2026 Financial Results and Highlights Recent Progress All three initial patients treated with RP-A501 under the modified pivotal Phase 2 protocol completed the protocol-defined safety observation period; no thrombotic mic

SEC EDGAR 8-K6 min
AUG 4
$RCKTMed

Rocket points to Danon gene therapy’s safety after Phase II protocol change

Rocket Pharmaceuticals said its RP-A501 Danon disease gene therapy has safely treated three Phase II patients after an FDA-triggered protocol change. The FDA allowed relaunch of NCT06092034 in Aug 2025. Rocket reports no capillary leak syndrome, blood vessel damage, or other serious adverse events since dosing with a recalibrated dose plus rituximab, sirolimus, and corticosteroids.

yahoo.com5 min
AUG 3
$RCKTMed

Why is Rocket Pharmaceuticals stock volatile today?

Investing.com reports Rocket Pharmaceuticals (RCKT) rose 0.6% pre-open after it said the first three patients treated under a revised Phase 2 protocol for RP-A501 Danon disease gene therapy showed no significant safety issues, including no thrombotic microangiopathy or capillary leak syndrome. The FDA lifted the clinical hold in mid-2025. Shares were $3.13 ahead of Aug 6 Q2 2026 earnings.

investing.com3 min
JUN 12
$RCKTMed

ROCKET PHARMACEUTICALS, INC. (RCKT): Completion of Acquisition or Disposition of Assets

ROCKET PHARMACEUTICALS, INC. (RCKT) filed an SEC Form 8-K — Completion of Acquisition or Disposition of Assets. false 0001281895 0001281895 2026-06-10 2026-06-10 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 10, 2026 R

SEC EDGAR 8-K2 min